RxDoctor Payments Data

Kimberly Spears, NP

Psychiatric/Mental Health · Boise, IDNPI 1558564138

Payments from drug & device makers

$764in general payments, 2019–2025

Across 24 payments — averaging $31.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$355
  • Otsuka America Pharmaceutical, Inc.$144
  • E.r. Squibb & Sons, L.L.C.$140
  • Neurocrine Biosciences, Inc.$53
  • Axsome Therapeutics, Inc.$36
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$23
  • plus $13 from 1 others

What the payments were for

  • Food & beverage$764100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$764 in reported general payments places this provider in the 50th percentile of 221 psychiatric/mental health providers in Idaho.

See all psychiatric/mental health providers in Idaho

Medicare billing

Part B allowed, 2024
$31,196
Medicare patients
96
Services billed
367

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate11$92,904
Invega SustennaPaliperidone Palmitate23$66,009
EmsamSelegiline13$27,303
Risperdal ConstaRisperidone Microspheres22$24,906
Paliperidone ErPaliperidone48$22,801
Lurasidone Hcl49$20,630
LybalviOlanzapine/Samidorphan Malate12$19,636
Aripiprazole168$11,603
Asenapine Maleate23$9,834
Quetiapine Fumarate297$4,996
Clozapine71$4,477
Divalproex Sodium ErDivalproex Sodium115$4,359
Clozapine OdtClozapine42$4,200
Lamotrigine OdtLamotrigine19$4,158
Fluphenazine Hcl37$3,784

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$53$92,90411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 221 psychiatric/mental health providers in Idaho.

Other psychiatric/mental health in Boise

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →